Evaxion's CMV Vaccine EVX-V1 Demonstrates Improved Infection Control in New Preclinical Data

summarizeSummary

Evaxion's EVX-V1 CMV vaccine candidate demonstrated improved control of acute infection, latency, and reactivation in preclinical models, supporting its multi-component AI-designed approach.

check_boxKey Events · Product Development and Regulatory · EVAX

• New Preclinical Data for EVX-V1

  AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice, complementing prior B-cell antigen data.

• Multi-Component Vaccine Strategy

  EVX-V1 combines novel AI-discovered antigens with optimized established antigens, targeting CMV from multiple angles to enhance protective potential.

• Presentation at IHW 2026

  Data was presented in a poster session at the International Herpesvirus Workshop 2026 in Montreal, Canada, on July 12, 2026.

• Unmet Medical Need

  No CMV vaccine is approved despite decades of research; CMV causes severe disease in immunocompromised individuals and infants, with a treatment market valued at $474.6M in 2023.

auto_awesomeAnalysis · EVAX · Life Sciences

At the International Herpesvirus Workshop 2026, Evaxion presented new preclinical data for its CMV vaccine candidate EVX-V1. The results show that AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. This builds on prior findings of reduced viral infection from novel B-cell antigens and superior neutralization from optimized structural antigens. The multi-component approach strengthens the vaccine's protective potential, addressing a market with no approved vaccine and significant unmet need. For a company with a market cap around $26 million, positive preclinical data for a major indication like CMV is a notable step forward, though still early-stage.